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ABSTRACT 
A simple and robust method for simultaneous determination of Trientine and N1-Acetyl Trientine in human plasma by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) was developed and validated. The analyte and internal standard were extracted from 200 μL plasma 
by liquid phase extraction. Chromatographic analysis was carried out on column Xtimate, C18 (4.6 x 50 mm) 5 μm with a flow rate of 1 mL/min, 
at 40˚C temperature. An isocratic elution method was applied using (A) Acetonitrile - 80% and (B) 10mM Ammonium Acetate in water - 20%.  
Detection and quantitation was done by multiple reactions monitoring in positive ionization with Q3 LCMS-8050, Shimadzu. Mass parameters 
1035.45/1030.55 m/z and 855.15/859.50 m/z on a triple quadrupole mass spectrometer were chosen for analysis of Trientine and N1-Acetyl 
Trientine. Linearity was established in human plasma covering the concentration range 10.009 ng/mL to 1000.571 ng/mL for Trientine and 
10.009 ng/mL to 1000.628 ng/mL for N1-Acetyl Trientine. Correlation coefficient was consistently greater than 0.99 for Trientine and N1-
Acetyl Trientine using Trientine-D4 and N1-Acetyl Trientine Trihydrochloride D4 as internal standards. Different parameters such as linearity, 
range, precision, accuracy, ruggedness and robustness, limit of detection (LOD) and limit of quantification (LOQ) were used for a full validation 
of this method. The results were found to be acceptable as per the guidelines of International Conference on Harmonization (ICH), CDER, 
EMA1,2,3,4,5. The developed and validated method was successfully applied to estimate Trientine and N1-Acetyl Trientine in a bioequivalence 
study in healthy human volunteers. Assay reproducibility was checked by reanalysis of samples near the Cmax and the elimination phase in the 
pharmacokinetic profile of the drug. 
Keywords: Trientine and N1-Acetyl Trientine, LC-MS/MS, Validation, ICH. 
 
Article Info: Received 27 March 2019;     Review Completed 03 May 2019;     Accepted 08 May 2019;     Available online 15 May 2019 
Cite this article as: 
Nair S, Dasandi B, Parmar D, Shivprakash,  Karia D. Sensitive and Rapid determination of Trientine and N1-Acetyl 
Trientine in Human Plasma by LC-MS/MS for bioequivalence study, Journal of Drug Delivery and Therapeutics. 2019; 
9(3):310-318   http://dx.doi.org/10.22270/jddt.v9i3.2660                            
*Address for Correspondence:  
Sheeba Nair, Synchron Research Services Private Limited, Synchron House, B/h Mondeal Park, Nr. Gurudwara, S-G Highway, Ahmedabad, India.  
 
 
1. INTRODUCTION 
Triethylenetetramine (TETA) also known as Trientine is, a 
CuII-selective chelator, commonly used for the treatment of 
Wilson's disease, which is an autosomal recessive genetic 
disorder, manifested by copper accumulation in the tissues 
of patients.  Recently, it has been shown that TETA can be 
used in the treatment of cancer because it possesses 
telomerase inhibiting and anti-angiogenesis properties. 
[Hea-Young Cho, Robert A. Blum, Tracey Sunderland, Garth J. 
S. Cooper, and William J. Jusko (2009)]6.  TETA is poorly 
absorbed with a bioavailability of 8 to 30%.  It is widely 
distributed in tissues with relatively high concentrations 
measured in liver, heart and kidney. It is mainly metabolized 
via acetylation and two major acetylated metabolites exist in 
human serum and urine. 
There are published analytical methods available in the 
literature for the determination of Trientine as a single 
analyte (Miyazaki et al., 1990)7 and with metabolites in 
different biological samples like rat plasma, rat serum brain 
tissue, mouse plasma (Marc Cerrada-Gimenez et al. 2011)8 
and in human plasma and urine (Lu J1 et al., 2007)9 and 
serum (Othmana et al., 2007)10. Triethylenetetramine 
compound was detected and measured using High 
Performance Liquid Chromatography (HPLC) methods 
(Othmana et al.10, 2007; G.J Cooper et al., 2008; K. Miyazaki et 
al.7, 1990) LC-MS-MS (Lu J1 et al., 2007)9 with fluorescence 
(Hea-Young Cho et al., 2009)6 or conductometric detection 
(E. B. Hansen et al., 1985)11. The conductometric method has 
poor sensitivity, while the fluorescence derivatization 
methods using various labeling reagents, all generate 
complex chromatograms and moreover, have been optimized 
to detect unchanged TETA alone. The method of using 4-(1-
Pyrene) butyric acid N-hydroxy succinimide ester (PSE) as a 
fluorescence-derivatizing agent is highly selective and 
sensitive but requires high temperatures for derivatization 
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to occur. The chromatograms obtained were complicated by 
the presence of many endogenous amino compounds.  
 
Fig: 1: Trientine (TETA) and N1-Acetyl Trientine 
(MAT) 
The method developed by Othmana et al., 2007; determined 
Trientine and its two metabolite in human serum using 
HPLC, has longer run time of 35 minutes and high limitation 
quantitation i.e., 0.125 mg/L for DAT and MAT and 0.0625 
mg/L for TETA.  The method developed by Lu J1 et al., 2007; 
determination of Trientine and its metabolite in plasma and 
urine using LC-MS, reported with a quantitation time of 8 
min by LLE method, but has a high limit of quantitation, i.e., 
0.25–16_M for TETA, MAT and DAT in plasma and urine. 
However, as reported the stability problem of underivatized 
TETA prevented the method from extending to large-scale 
clinical analysis for pharmacology. Serum TETA 
concentrations were determined using validated selective 
fluorometric liquid chromatographic method based on 
intramolecular excimer-forming derivatization and are 
separated within 25 minutes with limits of quantitation for 
serum TETA were 0.0625 mg/L (Hea-Young Cho et al., 2009). 
Refer table 1 for a comparative assessment of the reported 
literature. 
In the present work, a sensitive, simple and rapid LC-MS/MS 
method was developed, optimized and validated for the 
simultaneous determination of Trientine and its metabolite 
N1-acetyltriethylenetetramine in human plasma. Advantages 
of this method include shorter runtime that is needed to 
achieve high throughput analysis required for clinical, 
pharmacokinetic and bioequivalence studies. In addition to 
lower sample processing volume and lower sample injection 
volume, lower limit of quantitation achieved that permit 
applicability of the proposed method to estimate lower 
concentrations of drug in human plasma. We used 
derivatization method and achieved the required stability. 
More details are included in the results section. The method 
was applied for a bioequivalence study of 14 healthy Indian 
populations. Reproducibility in the measurement of study 
data has been successfully demonstrated by reanalysis of 
incurred samples. The method was successfully applied for 
bioequivalence study in healthy Indian subjects with 
required accuracy and precision. 
 
Table 1: Comparative assessment of chromatographic methods developed for analysis of Trientine and metabolites in human 
(1990-2017) 
Sr.  
No. 
Detection 
technique 
Extraction 
procedure 
Sample 
volume; 
injection 
volume 
Linear range Retention 
time (min); 
run time 
min 
Application  Ref. 
1 HPLC LLE 10 μL human 
plasma 
0.0625-5 mg/L  
(TETA) 
0.125-5 mg/L 
(MAT and DAT)  
TETA 
(23.7), 
MAT(17.7) 
and DAT 
(8.6), and 
HDA 
(16.9); 35  
PK, PD, and Metabolism of 
Trientine in Healthy Human 
Participants 
G.J 
Cooper 
et al., 
2008 
 
2 
LC_MS/MS LLE 100 μL 
human 
plasma/urine; 
50 μL 
0.25–16_M 
(TETA, MAT and 
DAT) 
 
TETA (2.3); 
8 
PK measurement in one healthy 
subject following oral dose and 7 
subjects urine samples from the 
diabetic patients 
Lu J1 et 
al., 2007 
3 HPLC LLE with 
derivatization 
25 μL human 
serum 
0.0625–5 mg/L 
(TETA) 0.125–5 
mg/L (MAT and 
DAT)  
35 PK measurement in one healthy 
subject following oral dose of 600 
mg. 
Othmana 
et al., 
2007 
4 Fluorimetric-
LC 
 
LC-based on 
intra 
molecular 
excimer 
forming 
derivatization 
- 0.0625 mg/L - 
3.0 mg/L 
25 PK and PD 
Modeling of a Copper-Selective 
Chelator 
in Healthy Adults 
Hea-
Young 
Cho et 
al., 2009 
 
5 HPLC-
flourometric 
SPE 0.5 mL 
plasma; 20-50 
μL  
40 μg/mL -  
100ng/mL 
- Determination of Trientine in 
plasma of patients  
K. 
Miyazaki 
et al., 
1990 
6 LC-MS/MS LLE 200 μL 
human 
plasma; 10 μL  
10.009 ng/mL -
1000.571 ng/mL 
(TETA) 10.009 
ng/mL to 
1000.628 ng/mL 
for N1-Acetyl 
Trientine. 
10 Bioequivalence study with 250 
mg of oral administration 
Trientine in 14 healthy Indian 
subjects  
PM 
 HPLC: High performance liquid chromatography, LC-MS/MS: Liquid chromatography- tandem mass spectrometry, LLE: Liquid-
liquid extraction, SPE: Solid phase extraction, TETA: Trientine, MAT: N1-Acetyl Trientine: DAT: N1-Diacetyl Trientine , PK: 
Pharmacokinetic, PD: Pharmacodynamic, PM: Present method,  
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2.  EXPERIMENTAL 
2.1.  Chemicals and reagents 
The reference standard of Trientine (purity 99%), N1-Acetyl 
Trientine (purity 99.4%), Trientine-D4 (purity 99.6%), N1-
Acetyl Trientine Tetramine Trihydrochloride D4 (purity 
99.1%) were purchased from Vivan life sciences (P) Ltd. 
(Mumbai, India). Ammonium Acetate (GR/AR Grade), 
Methanol [HPLC Grade], Acetonitrile [HPLC Grade], Borax 
(AR/GR Grade), FMOC (Fluorenylmethyloxycarbonyl 
chloride) were purchased from Merch Specialties Pvt. Ltd. 
(Mumbai, India). Milli - Q / HPLC Grade Water, Human 
Plasma (K3EDTA), Whole Blood (K3EDTA) were utilized. 
Column Xtimate, C18 (4.6 x 50 mm) was purchased from 
Phenomenex India (Hydrebad, India). The detection was 
done using LCMS instrument Nexera X2 highest pressure 
UHPLC, [LCMS-8050, Shimadzu] and lab solutions for data 
processing.  
2.2.  Instrumentation and chromatographic 
conditions 
The chromatography was performed on Nexera X2 UHPLC 
System (Shimadzu LCMS 8050) with cooling auto-sampler 
and column oven enabling temperature control of the 
analytical column. The column utilized was Xtimate, C18 (4.6 
x 50 mm) 5 μm at 40˚C temperature.  An isocratic elution 
method was applied using (A) Acetonitrile - 80% and (B) 
10mM Ammonium Acetate in water - 20%.  Detection was 
done by Q3 LCMS-8050, Shimadzu with ESI (+) ion mode for 
Trientine and N1-Acetyly Trientine. The auto-sampler was 
maintained at 5˚C and the injection volume was 10μL. Total 
run time for each sample analysis was 10 min. The optimized 
Multiple Reaction Monitoring (MRM) conditions of mass 
spectroscopy applied in the method development are the 
transitions of m/z 1035.45→1035.45 for Trientine, m/z 
1039.55→1039.55 for Trientine D4, m/z 855.15→855.15 for 
N1-Acetyl Trientine and m/z 859.50→859.50 for N1-Acetyl 
Trientine D4 respectively, with a scan time of 100 ms per 
transition. The heat block temperature was 300˚C, nebulizing 
gas flow 3.0 L/min, drying gas flow 10.0 L/min, CID gas 270 
kpa and HESI positive /negative interface voltage +/- 4000 
volts. 
Quantitation was achieved by MS/MS detection in positive 
ion mode using Shimdzu LCMS-8050 mass spectrometer, 
equipped with Heated Electro Spray Ionization (HESI) 
interface. Lab solution Version 6 software was used for 
instrument control and data acquisition.  
2.3.  Preparation of stock solutions calibration 
standards and quality control samples  
A stock solution of 1.0 mg/mL concentration of Trientine, N1 
Acetyl Trientine and a stock solution of 0.5 mg/mL 
concentration of Trientine, N1 Acetyl Trientine were 
prepared by dissolving requisite amount in methanol. 
Working solutions were prepared by diluting stock solution 
by methanol. Stock and working solutions were stored in 
refrigerator at 2 to 8°C.  Calibration Standards (CSs) and 
Quality Controls (QCs) samples were prepared by spiking 
blank plasma with working solutions. The concentration of 
CSs were made in the range of 10-1000 ng/mL and that of QC 
samples were prepared at five levels (10, 28, 102, 512, 800 
ng/mL) and are given in table 2. 
2.4  Sample extraction procedure 
To an aliquot of 200 μL of spiked plasma/subject samples, 50 
μL of working solution was added and vortexed for 10 
seconds.  The solutions were made alkaline by adding 100 μL 
of 133 mM Borax solution and briefly vortexed. Added 600 
μL of acetonitrile and vortexed for 3 min and then 
centrifuged at 4000 rpm for 10 min. The supernatant was 
collected, 200 μL of FMOC solution was added and vortex 
mixed. The samples were then kept for complete 
derivatization for 10 min. Following centrifugation at 4000 
rpm for 5 min, the samples were collected in prelabelled 
autosampler vials and 10 μL was used for injection in LC-
MS/MS system. 
2.5.  Method Validation 
The method was validated to meet the acceptance criteria of 
industrial guidance for the bioanalytical method validation. 
The method was validated for selectivity, linearity, precision, 
accuracy, matrix effect, recovery and stability. [Guideline on 
bioanalytical method validation; 
EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. Committee 
for Medicinal Products for Human Use (CHMP) 21 July 2011, 
FDA Guidance; (September 2013) Guidance for Industry, 
Bioanalytical Method Validation]. 
2.5.1  Specificity and Selectivity 
Specificity of the method was checked for any interferences 
in eight different lots of human blank plasma including one 
lipemic and one hemolyzed with the proposed extraction 
procedure. Selectivity was assessed, by comparing the 
chromatograms of blank plasma and plasma spiked with 
lowest standard from eight various sources including lipemic 
and hemolyzed (or donors). Cross analyte effect (cross talk) 
was evaluated by spiking the highest concentration 
individually and monitored all Multiple Reaction Monitoring 
(MRM) channels for interferences. 
2.5.2  Precision and accuracy 
All validation experiments were carried out at five (LOQQC, 
LQC, MQC-1, MQC-2 and HQC) QC levels. For the determining 
of intraday accuracy and precision, a replicate (n=6) analysis 
of plasma samples were performed on the same day. The 
inter-day accuracy & precision were assessed by analysis of 
three batches on different days. The precision was expressed 
as Relative Standard Deviation (RSD %) and accuracy as 
Relative Error (RE %).  
2.5.3  Calibration Curve 
Plotting of the peak area ratio of the transition pair of 
analytes to that of IS against the nominal concentration of 
calibration standards was done to obtain calibration curves. 
The concentrations used of Trientine and N1 Acetyl Trientine 
calibration curves were 10, 20, 50, 150, 500, 751, 900, 1000 
ng/mL, while 28, 512, 800 were used for its LQC, MQC, HQC 
respectively.  Blank sample and zero samples were run with 
each calibration curve. The acceptance criterion for each 
back-calculated standard concentration was + 15% deviation 
from the nominal value except at LLOQ, which was set at + 
20%. 
2.5.4  Recovery and Matrix effect 
The recovery of Trientine, N1-Acetyl Trientine and ISs were 
determined by comparing the responses of the analytes 
extracted from replicate QC samples (n = 6) with the 
response of analytes from post extracted plasma standard 
sample at equivalent concentration. Recovery was 
determined at low, mid and high-quality control 
concentrations, whereas the recovery of the ISs were 
determined at a single concentration. The matrix of plasma 
constituents over the ionization of analytes and IS were 
determined by comparing the responses of the post-
extracted plasma standard QC samples (n = 6) with the 
response of analytes from neat samples at equivalent 
concentrations. Matrix effect was determined at two levels 
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with six various sources of plasma (out of eight, six were 
normal K3EDTA plasma, one was lipemic and one was 
hemolyzed with the same anticoagulant) (LQC and HQC) for 
Trientine and N1-Acetyl Trientine and for ISs.  Dilution 
integrity was performed to extend the upper concentration 
limit with acceptable precision & accuracy.  
2.5.5  Dilution Integrity 
Trientine and N1-Acetyl Trientine separately spiked in 
human plasma samples, prepared at concentrations 2001.14 
ng/mL for Trientine and 2001.256 ng/mL for N1-Acetyl 
Trientine, were diluted with human plasma two folds in six 
replicates and then analyzed. 
2.5.6  Stability 
Process sample stability was evaluated by re-injecting the 
same sample with freshly spiked calibration curve and 
quality control samples, which (stability samples) were 
stored at 5ºC for 161.48 hr. Bench top stability was evaluated 
for 6 hr and compared with freshly spiked plasma samples. 
The freeze-thaw stability was determined by comparing the 
stability samples that had been frozen and thawed five times, 
with freshly spiked quality control samples. Long term 
stability was evaluated by analyzing at low and high-quality 
control samples those were stored at -20ºC for 36 days 
together with freshly spiked calibration & quality control 
standards. All stability evaluations were based on back 
calculated concentrations. Samples considered to be stable if 
assay values were within the acceptable limits of accuracy 
(i.e., ±15% S.D.) and precision (i.e., 15% R.S.D.).  Stability in 
whole blood was evaluated by spiking the known 
concentration at two levels in whole blood in two different 
aliquots. One aliquot was kept at room temperature while 
one was at 2-8 ºC for an hour. After an hour one more aliquot 
was freshly spiked in whole blood at same concentration 
level and all aliquots (stability) were centrifuged for plasma 
separation. These plasma samples were processed as per 
described sample preparation and their response ratio was 
compared.  
2.6  Pharmacokinetic Application 
The application of the method was demonstrated by a 
bioequivalence study in 14 healthy Indian subjects using a 
single dose of (Trientine Hydrochloride capsules USP 250 mg 
of an Indian Pharmaceutical Company) under fasting 
conditions. Each volunteer was judged to be in good health 
through medical history, physical examination and routine 
laboratory tests. The design of study comprised of a 
randomized, open label, single dose, two treatments, two 
periods, two sequence crossover bioequivalence study of 
Trientine Hydrochloride capsules USP 250 mg in 14 healthy 
human volunteers. The ethics committee approved the 
protocol and the volunteers provided informed written 
consent to participate in the study according to the 
principles of the Declaration of Helsinki. The study was 
conducted strictly in accordance with guidelines laid down 
by International Conference on Harmonization and USFDA. 
Plasma concentration–time data of Trientine and N1-Acetyl 
Trientine was analyzed by non-compartmental method using 
Kinetica Version 4.4 (Thermo USA). Regarding AUC0–t, 
AUC0–∞ and Cmax, bioequivalence was assessed by means 
of an analysis of variance (ANOVA) and calculating the 
Standard 90% and Confidence Intervals (90% CIs) of the 
ratios test/reference (logarithmically transformed data). 
Assay reproducibility was checked by reanalysis of samples 
near the Cmax and the elimination phase in the 
pharmacokinetic profile of the drug. The results were 
compared with initial pharmacokinetic study using the same 
procedure. As per the acceptance criterion at least two-third 
of the original results and repeat results should be within 
20% of each other. 
3.  RESULT AND DISCUSSION 
3.1  LC-MS/MS method development 
There is one method reported with a less quantitation time 
of 8 min, however the LLOQ of the reported method (LLOQ 
0.25 M) was much higher than the newly developed method. 
Moreover, as reported the stability problem of underivatized 
TETA prevented the method from extending to large-scale 
clinical analysis for pharmacology. The newly developed 
method has a much sensitive quantification of LLOQ (10.009 
ng/mL) with minimum run time of 10 min. Advantages of 
this method include shorter runtime that is needed to 
achieve high throughput analysis and required for clinical, 
pharmacokinetic and bioequivalence studies. In addition to 
lower sample processing volume and lower sample injection 
volume, lower limit of quantitation achieved that permit 
applicability of the proposed method to estimate lower 
concentrations of the studied drug in human plasma. The 
method was successfully applied for bioequivalence study in 
healthy Indian indicant subjects with required accuracy and 
precision. We used derivatization method and achieved the 
required stability and the method was applied for a 
bioequivalence study of 14 healthy Indian populations. 
Reproducibility in the measurement of study data has been 
successfully demonstrated by reanalysis of incurred samples.   
Flow injection method with standard solution was used to 
optimize ESI conditions during tuning.   Full scan mass 
spectra was acquired for positive mode for Trientine and N1-
Acetyl Trientine with their labeled internal standards 
respectively. Trientine and N1-Acetyl Trientine showed 
higher responses in positive ionization mode. The major 
fragments ions of these molecules were observed in the 
product ion scan of the collision cell.  Based on the analytes 
properties deuterated analogs of Trientine and N1-Acetyl 
Trientine (Trientine D4 And N1-Acetyl Trientine 
trihydrochloride D4) were chosen as internal standards. 
Trientine and N1-Acetyl Trientine ionized efficiently in 
positive mode. In mass spectrometry, the parameters 
including temperature, flow rate of drying gas, collision gas 
(medium), nebulizing gas and desolvation temperature were 
optimized to obtain maximum response of the 
fragmentation. As both analyte have very low mass, i.e., 147 
and 189 and its fragmentation provided unstable as well as 
low intensity of product mass. Which lead to high noise of 
baseline and reported polyamines interference the 
identification of the compounds because some polyamines 
have similar structures and molecular weights (Ref (Cooper 
et al, 2007).  Therefore, we preferred derivatization with 
FMOC and the method developed in pseudo MRM mode. 
Parent mass was monitored by Q1 and Q3 for estimation and 
separated both analytes chromatographically. 
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Below is the structure of the analyte with derivatized analyte 
 
Q1 and Q3 Scan results of Trientine and N1-Acetyl Trientine  
The optimized Multiple Reaction Monitoring (MRM) 
conditions of mass spectroscopy applied in the method 
development are the transitions of m/z 1035.45→1035.45 
for Trientine, m/z 1039.55→1039.55 for Trientine D4, m/z 
855.15→855.15 for N1-Acetyl Trientine and m/z 
859.50→859.50 for N1-Acetyl Trientine D4 respectively, with 
a scan time of 100 ms per transition. The heat block 
temperature was 300˚C, nebulizing gas flow 3.0 L/min, 
drying gas flow 10.0 L/min, CID gas 270 kpa and HESI 
positive /negative interface voltage +/- 4000volts. 
A variety of mobile phases and columns were tried to 
develop a suitable method for the simultaneous estimation of 
Trientine and N1-Acetyl Trientine. Chromatographic 
conditions were optimized by using different ratios of 
acetonitrile-buffer and ammonium acetate in water as 
mobile phase using different C 18 columns i.e., chromatopak 
peerless basic C 18 and Xtimate C18. In case of peerless basic 
column, analytes signal found very less with low resolution. 
The best resolution with increase in signal strength for both 
analytes were found with welch Xtimate C18. The retention 
time of Trientine, Trientine D4 and N1-Acetyl Trientine, and 
N1-Acetyl Trientine D4 were 8.22 min, 8.22 min, 2.04 and 
2.04 min, respectively. The total chromatographic run time 
was 10 min. The reinjection reproducibility of (%CV) in the 
measurement of retention time was < 1.3%. 
3.2  Assay validation results  
3.2.1 Selectivity, Specificity and Linearity 
The results of system suitability, autosampler and column 
carryover, ruggedness and dilution integrity suggest 
acceptable assay performance as evident from the data 
presented in table 2. The selectivity of the method was 
evident from the chromatograms of double blank plasma, 
plasma spiked with Trientine D4 and Trientine at different 
concentration level and subject sample at Cmax level. No 
interface due to endogenous compound was observed at the 
retention time of Trientine and Trientine D-4. Furthermore, 
none of the commonly used medications by human 
volunteers interfered at their retention times. The 
calibration curves showed good linearity over the 
established concentration range of 10.009 ng/mL to 
1000.571 ng/mL (r2 >0.99) for Trientine and 10.009 ng/mL 
to 1000.628 ng/mL for N1-Acetyl Trientine.  
Representative Chromatogram of Double Blank, Blank and 
LLOQ Sample is provided below ;
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Fig 1: Double Blank     Fig 2: Blank 
 
Fig 3: LLOQ 
 
Fig. 4: Chromatographic separation of Trientine, N1-Acetyl Trientine trihydrochloride, Trientine D4 and N1-Acetyl 
Trientine trihydrochloride D4 (Internal Standards) 
The mean value of slope, intercept, accuracy, and precision date in the measurement of calibration concentrations are shown in 
table 2.  
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Table 2:  Summary of the Experimental Parameters of Trientine in K2EDTA Human Plasma 
Experimental Parameters Results Results 
Analyte  Trientine N1-Acetyl Trientine  
Biological Matrix  K2 EDTA Human Plasma K2 EDTA Human Plasma 
Specificity and Selectivity % CV  1.2% 3.5% 
Analytical range  10.009 ng/mL to 1000.571 ng/mL 10.009 ng/mL to 1000.628 ng/mL 
Sensitivity:  
Precision, Accuracy  
 
2.9%, 91.3% 
 
6.6%, 92.7% 
Recovery: 
Trientine recovery (%) 
Trientine D4 recovery (%)  
 
93.79% 
89.37%  
 
92.17%  
89.55% 
Linearity range (ng/mL) 9.745 ng/mL to 957.340 ng/mL 9.925 ng/mL to 971.109 ng/mL 
Calibration Standards (ng/mL) 10, 20, 50, 150, 500, 751, 900, 1000 10, 20, 50, 150, 500, 751, 900, 1000 
Quality control samples (ng/mL) 10, 28, 102, 512, 800 10, 28, 102, 512, 800 
LLOQ (S/N ratio) 10.009 ng/mL (> 10)  10.009 ng/mL (> 10)  
Weighing factor  1/x2 1/x2 
Correlation coefficient (r2 ) > 0.99 > 0.99 
 
3.2.2 Precision and Accuracy  
Six replicates at low, medium and high-quality control 
concentration for Trientine and N1-Acetyl Trientine were 
prepared for precision and accuracy determination. The 
intra-day and inter-day precision (%CV) and accuracy values 
across the QC levels for Trientine and N1-Acetyl Trientine 
are tabulated in table 3 and 4 respectively. The Limit of 
Quantitation (LOQ) was respectively 10.009 ng/mL.  
 
Table 3: Intra assay precision and accuracy for Trientine and N1- Acetyl Trientine. 
Compound N Concentration (ng/mL) %CV Recovery (%) 
Added Measured 
Trientine 6 
6 
6 
6 
6 
10.04 
28.68 
102.45 
512.29 
800.45 
11.13 
32.11 
113.5 
539.13 
817.97 
2.7 
0.8 
1.2 
2.3 
1.4 
110.9 
111.9 
110.8 
105.2 
102.2 
N1 Acetyl Trientine 6 
6 
6 
6 
6 
10.03 
28.67 
102.41 
512.06 
800.09 
11.09 
32.90 
115.46 
569.26 
861.27 
3.8 
3.0 
4.2 
3.7 
4.3 
110.5 
114.7 
112.7 
111.2 
107.6 
 
Table 4: Inter-assay precision and accuracy for Trientine and N1- Acetyl Trientine. 
Compound N Concentration (ng/mL) %CV Recovery (%) 
Added Measured 
Trientine 18 
18 
18 
18 
18 
10.04 
28.68 
102.45 
512.29 
800.54 
10.32 
30.93 
111.05 
527.37 
804.10 
6.7 
3.0 
1.8 
2.4 
2.0 
102.8 
107.8 
108.4 
102.9 
100.5 
N1 Acetyl Trientine 18 10.03 
28.67 
102.41 
512.06 
800.09 
10.51 
31.28 
112.02 
540.28 
838.80 
4.9 
4.4 
3.6 
4.6 
3.5 
104.8 
109.1 
109.4 
105.5 
104.8 
 
3.2.3 Extraction Recovery  
The % recovery and extraction recovery for Trientine and 
N1-Acetyl Trientine are presented in table 5. Six replicates at 
low, medium and high, quality control concentration for 
Trientine and N1-Acetyl Trientine were prepared for 
recovery determination. The mean recovery was 88.11%, 
94.38% and 98.87% at HQC, MQC & LQC level respectively 
for Trientine and 88.22%, 92.50% and 95.79% at HQC, MQC 
& LQC level respectively for N1-Acetyl Trientine. The mean 
recovery was 89.37% and 89.55% for IS Trientine D4 and 
N1-Acetyl Trientine D4 respectively. The presence of 
unmonitored, co-eluting compounds from the matrix can be 
directly impact the overall performance of a validated 
method. It is necessary to evaluate MFs to assess the matrix 
effect. Matrix effect was also checked in lipemic and 
hemolyzed plasma samples together with normal K3EDTA 
plasma. This was determined by examining the precision 
(%CV) values of the slopes of the calibration curves prepared 
from eight different plasma lots, which included six K3EDTA, 
one lipemic and one hemolyzed plasma samples. Average 
matrix factor values (matrix factor = response of post-spiked 
concentrations/ response of neat concentrations) obtained 
for Trientine  and N1-Acetyl Trientine were 0.96 (CV 2.1%, n 
= 6+2) and 0.94 (CV 2.1%, n = 6+2) at LQC and 1.0 (CV 2.1%, 
n = 6+2) and 1.0 (CV 3.0%, n = 6+2) for HQC, respectively, 
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whereas on ISs it was found to be 0.96 (CV 5.1%, n = 6+2) for 
Trientine D4 & 1.0 (CV 5.0%, n = 6+2)  for N1-Acetyl 
Trientine D4 at tested concentration of 500 ng/mL & 100 
ng/mL  respectively. There were no significant matrix effects 
observed for any of the analytes or the ISs.  
 
Table 5: Recovery (%) and Extraction recovery for Trientine and N1- Acetyl Trientine for human plasma. 
Recover (%) Trientine 
(%) 
Precision 
(%) 
N1- Acetyl 
Trientine (%) 
Precision 
(%) 
Trienetine D4 
(%) 
N1- Acetyl 
Trientine D4 (%) 
High 98.60 1.9 98.52 3.3 101.59 
(precision 1.8) 
101.46 
(precision 3.3) Medium  105.04 2.4 103.17 3.4 
Low QC 100.86 2.6 100.0 5.7 
Mean recovery 101.50 - 100.56 - 101.59 101.46 
Extraction Efficiency (Area) (%) 
High 88.11 0.8 88.22 4.1 89.37 
(precision 2) 
89.55 
(precision 3) Medium  94.38 7.8 92.50 8.8 
Low QC 98.87 3.3 95.79 6.7 
Mean recovery 93.79 - 92.17 - 89.37 89.55 
 
3.2.4 Dilution Integrity (DI) 
Dilution integrity for Trientine was evaluated by preparing 
DI samples with about 2 times the concentration of the high 
CC. Take 0.25 mL volume from drug dilution (200114.15 
ng/mL for Trientine and 2000125.59 ng/mL for N1 Acetyl 
Trientine) and spike of this solution in plasma to get final 
concentration of 2001.14 ng/mL. This was diluted to 1/5th 
and 1/10th, processed as per standard test method and 
analyzed against a calibration curve. 
The accuracy of both the dilutions (1/5th and 1/10th) were 
102.7% and 105.2% for Trientine and 98.0% and 101.8% for 
N1 Acetyl Trientine, which is within the acceptance range of 
%CV <15%. The precision of the samples for both the 
dilutions (1/5th and 1/10th) were 1.7% and 1.4% for 
Trientine and 8.5% and 6.7% for N1-Acetyl Trientine, which 
is within the acceptance range of %CV <15%. 
3.2.5 Sample Stability 
Stock solutions kept for short term and long-term stability as 
well as spiked plasma solutions showed no evidence of 
degradation under all the studied conditions. The stability of 
the analytes in human plasma under different temperature 
and timing conditions were evaluated. QC samples were 
subjected to long-term storage conditions (-20°C) and to 
freeze–thaw stability studies. All the stability studies were 
conducted at two concentration levels with six 
determinations for each. For process stability, the results 
indicated that the difference in the back-calculated 
concentration are stable at least for 161:48 hr at 5°C in the 
auto-sampler. The % mean ratio for the Low and High QCs 
were 90.01% and 91.98% for Trientine and 90.39% and 
93.93% for N1-Acetyl Trientine, which is within acceptable 
range of 85%-115%. 
For bench top stability, the results allowed us to conclude 
that both analytes are stable for at least 6:45 hr at room 
temperature in plasma samples. The % mean ratio for the 
Low and High QCs were 100.26% and 98.22% for Trientine 
and 98.07% and 96.86% for N1-Acetyl Trientine. Freeze and 
thaw stability results indicated that the repeated freeze and 
thawing (five cycles) did not affect the stability of Trientine 
And N1-Acetyl Trientine. Long-term stability of the analytes 
in plasma at -20°C was found to be stable for at least 36 days. 
The % mean ratio for the high and low QCs were 105.10% 
and 103.87% for Trientine and 102.83% and 97.78% for N1-
Acetyl Trientine, which is within acceptable range of 85%-
115%. For blood sample stability the % change for stability 
samples was ˂ 5% from the comparison samples for 
Trientine And N1-Acetyl Trientine at LQC & HQC level. 
3.3  Application to a Bioequivalence Study 
Blood samples were obtained following oral administration 
of Trientine Hydrochloride capsules USP 250 mg into 
K3EDTA vacutainer solution as an anticoagulant. Plasma was 
separated by centrifuging the blood using an eppendorf 
centrifuge at 4000 rpm for 5 min and stored frozen at 
−20±5˚C until analysis. An aliquot of 0.2 mL of thawed 
plasma samples were spiked with IS and processed. Plasma 
concentration–time data of Trientine and N1-Acetyl 
Trientine was analyzed by non-compartmental method using 
Kinetica Version 4.4 (Thermo USA). Regarding AUC0–t, 
AUC0–∞ and Cmax, bioequivalence was assessed by means 
of an Analysis of Variance (ANOVA) and calculating the 
standard 90% Confidence Intervals (90% CIs) of the ratios 
test/reference (logarithmically transformed data). The mean 
plasma concentration-time curves for the two formulations 
are represented in Fig. 5. Pharmacokinetic parameters 
derived from these curves are presented in table 6. 
 
 
Fig 5: Mean plasma concentration-time linear plots of Trientine after administration of (test and reference) Trientine 
formulation to 14 healthy Indian Subjects 
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Table 6: Pharmacokinetic parameters of Trientine and N1-Acetl Trientine following oral administration of one Trientine 
Hydrochloride capsules USP 250 mg 
 
Pharmacokinetic 
Parameters 
Geometric Mean (%CV) Arithmetic Mean ± SD 
Trientine N1-Acetyl Trientine 
Test Formulation 
(n=14) 
Reference  
Formulation 
(n=14) 
Test Formulation 
(n=14) 
Reference  
Formulation 
(n=14) 
Cmax (ng/mL) 
798.60 (41.11)  
901.11 ± 267.43 
721.32 (53.46) 
824.00 ± 463.17 
727.36 (33.21) 
764.08 ± 267.53 
707.17 (26.99) 
796.38 ± 228.63 
AUC(0-t) (ng.h/mL) 
2865.10 (42.82) 
3210.22 ±1399.19 
2533.10 (44.63) 
3014.12 ± 1875.38 
6823.02 (22.17) 
7101.36 ± 2263.26 
6654.54 (23.76) 
6746.21 ± 2359.39 
AUC(0-inf) 
(ng.h/mL) 
3138.11 (44.75) 
3346.40 ±1776.39 
2903.31 (64.34) 
3103.77 ± 2237.43 
7364.11 (29.03) 
7893.33 ± 3318.67 
7012.31 (35.84) 
7503.32 ± 3908.62 
% AUCextra 
4.12 (53.43) 
5.43 ± 3.67 
3.367 (79.01) 
3.90 ± 4.36 
5.21 (40.12) 
5.88 ± 3.47 
5.06 (33.92) 
5.22 ±3.87 
Tmax (h)* 1.38 (0.17 -3.00) 1.26 (0.50- 2.00) 5.00 (3.50 -6.00) 4.75 (3.00- 6.00) 
 
4 CONCLUSIONS 
The described LC-MS/MS method provides fast, sensitive and 
selective procedure for simultaneous determination of 
Trientine And N1-Acetyl Trientine in human plasma. The 
analytes in this method were free from ion suppression 
effects generated by matrix. As an interference free and 
sensitive method to be used for bioequivalent study 
applicability we have adopted a psudo method. From the 
results of all the validation parameters, we can conclude that 
the present method can be useful for bioequivalence studies 
with desired precision and accuracy. The method can be 
useful for the analysis of larger number of samples as it uses 
a sample extraction procedure and requires low sample 
volume is highly selective and has a short assay time. 
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